Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. Earnings Recaps

AXSM Health Care 1 recap
Q3 2025 Nov 5, 2025

Axsome Therapeutics reported robust Q3 2025 results, with total revenue rising 63% year-over-year to $171 million, driven by strong demand for AUVELITY and steady growth of SUNOSI.

Key takeaways
  • AUVELITY sales reached $136.1 million, a 69% increase year-over-year, reflecting strong market traction.
  • SUNOSI revenues grew 35% year-over-year to $32.8 million, demonstrating ongoing commercial momentum.
  • Axsome submitted a supplemental NDA for AXS-05 in Alzheimer's disease agitation and plans to initiate multiple Phase III trials across ADHD and narcolepsy.
  • The company is well-positioned with a deep late-stage pipeline and a diverse portfolio of therapies addressing significant unmet needs in CNS health.
Full recap